2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Currently, the quality outcome measures for palliative and end-of-life care focus more on end-of-life than upstream palliative care.
Outcomes for patients with hematologic malignancies appear to be worse across the board when managed by these measures compared with patients with solid tumors, says LeBlanc.
Related Content: